AVIGAD FELDMAN: Open Payments
NPI 1073977245 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,215 in 38 payments from 14 companies in 2025. Trend: 2023 $791 · 2024 $887 · 2025 $1,215
Food & beverage: $1,215
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 5 | $190 |
| ABBVIE INC. | 3 | $167 |
| AstraZeneca Pharmaceuticals LP | 9 | $164 |
| PFIZER INC. | 3 | $160 |
| Janssen Pharmaceuticals, Inc | 4 | $150 |
| Lilly USA, LLC | 2 | $143 |
| Novo Nordisk Inc | 3 | $59 |
| Aimmune Therapeutics, Inc. | 2 | $43 |
| Exact Sciences Corporation | 2 | $40 |
| Astellas Pharma US Inc | 1 | $33 |
Products named: PREVNAR 20, SPRAVATO, REPATHA, KISUNLA, AIRSUPRA, OTEZLA, ZENPEP, FARXIGA.
Industry payments across PA — which companies pay providers there.
